Recursion Pharmaceuticals, Inc. – NASDAQ:RXRX
Founder-led company
Recursion Pharmaceuticals stock price today
$5.01
-2.38
-32.21%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 2 days
Recursion Pharmaceuticals stock price monthly change
-11.60%
month
Recursion Pharmaceuticals stock price quarterly change
-11.60%
quarter
Recursion Pharmaceuticals stock price yearly change
-30.94%
year
Recursion Pharmaceuticals key metrics
Market Cap | 2.37B |
Enterprise value | 652.61M |
P/E | -5.01 |
EV/Sales | 16.37 |
EV/EBITDA | -2.86 |
Price/Sales | 28.90 |
Price/Book | 2.37 |
PEG ratio | -0.27 |
EPS | -1.6 |
Revenue | 45.80M |
EBITDA | -349.58M |
Income | -354.11M |
Revenue Q/Q | 13.68% |
Revenue Y/Y | -1.53% |
Profit margin | -601.05% |
Oper. margin | -616.74% |
Gross margin | -21.16% |
EBIT margin | -616.74% |
EBITDA margin | -763.23% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeRecursion Pharmaceuticals stock price history
Recursion Pharmaceuticals stock forecast
Recursion Pharmaceuticals financial statements
| Jun 2023 | 11.01M | -76.72M | -696.5% |
|---|---|---|---|
| Sep 2023 | 10.10M | -93.01M | -920.78% |
| Dec 2023 | 10.89M | -92.99M | -853.88% |
| Mar 2024 | 13.79M | -91.37M | -662.41% |
| Mar 2024 | 13.79M | -91.37M | -662.41% |
|---|---|---|---|
| Sep 2025 | 14.3M | -146.88M | -1027.2% |
| Oct 2025 | 15.45M | -145.15M | -939.49% |
| Dec 2025 | 16.39M | -145.15M | -885.07% |
Analysts Price target
Financials & Ratios estimates
| 2024-02-27 | -0.46 | -0.4 |
|---|
| Jun 2023 | 666699000 | 197.73M | 29.66% |
|---|---|---|---|
| Sep 2023 | 630825000 | 192.85M | 30.57% |
| Dec 2023 | 653699000 | 190.26M | 29.11% |
| Mar 2024 | 557847000 | 156.69M | 28.09% |
| Jun 2023 | -67.46M | -2.05M | 3.78M |
|---|---|---|---|
| Sep 2023 | -72.92M | -347K | 53.76M |
| Dec 2023 | -74.07M | -2.48M | 80.65M |
| Mar 2024 | -102.3M | -6.65M | 13.89M |
Recursion Pharmaceuticals alternative data
| Sep 2023 | 550 |
|---|---|
| Oct 2023 | 550 |
| Nov 2023 | 550 |
| Dec 2023 | 550 |
| Jan 2024 | 550 |
| Feb 2024 | 550 |
| Mar 2024 | 500 |
| Apr 2024 | 500 |
| May 2024 | 500 |
| Jun 2024 | 500 |
| Jul 2024 | 500 |
Recursion Pharmaceuticals other data
40.19%
-31.14%
of RXRX is owned by hedge funds
95
-47
70.54M
-53.15M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Feb 2024 | 0 | 78054 |
| Mar 2024 | 0 | 224427 |
| Apr 2024 | 0 | 215465 |
| May 2024 | 0 | 91350 |
| Aug 2024 | 0 | 32447 |
| Sep 2024 | 0 | 98894 |
| Oct 2024 | 0 | 110341 |
| Nov 2024 | 0 | 81447 |
| Dec 2024 | 0 | 40000 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | GIBSON CHRISTOPHER director, officer.. | Class A Common Stock | 20,000 | $7.12 | $142,400 | ||
Sale | GIBSON CHRISTOPHER director, officer.. | Class A Common Stock | 20,000 | $7.16 | $143,200 | ||
Sale | GIBSON CHRISTOPHER director, officer.. | Class A Common Stock | 20,000 | $7.35 | $147,000 | ||
Sale | GIBSON CHRISTOPHER director, officer.. | Class A Common Stock | 20,000 | $7.74 | $154,800 | ||
Option | SECORA MICHAEL officer: Chief Fi.. | Class A Common Stock | 39,375 | $2.22 | $87,413 | ||
Sale | SECORA MICHAEL officer: Chief Fi.. | Class A Common Stock | 15,000 | $7.66 | $114,870 | ||
Option | SECORA MICHAEL officer: Chief Fi.. | Stock Option (Right to Buy) | 39,375 | $2.22 | $87,413 | ||
Sale | BORGESON BLAKE director | Class A Common Stock | 11,447 | $7.64 | $87,455 | ||
Option | SECORA MICHAEL officer: Chief Fi.. | Class A Common Stock | 39,375 | $2.22 | $87,413 | ||
Sale | SECORA MICHAEL officer: Chief Fi.. | Class A Common Stock | 15,000 | $7.64 | $114,630 |
| Patent |
|---|
Application Filling date: 18 Feb 2021 Issue date: 18 Aug 2022 |
Application Filling date: 27 Jan 2022 Issue date: 28 Jul 2022 |
Grant Filling date: 14 Nov 2018 Issue date: 19 Jul 2022 |
Grant Filling date: 27 Jul 2020 Issue date: 14 Jun 2022 |
Application Filling date: 23 Nov 2020 Issue date: 26 May 2022 |
Application Filling date: 11 Mar 2020 Issue date: 19 May 2022 |
Application Filling date: 17 Nov 2020 Issue date: 24 Feb 2022 |
Application Filling date: 27 Jul 2020 Issue date: 27 Jan 2022 |
Application Filling date: 27 Jul 2020 Issue date: 27 Jan 2022 |
Application Filling date: 20 Jul 2020 Issue date: 20 Jan 2022 |
| Quarter | Transcript |
|---|---|
| Q1 2024 9 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 27 Feb 2024 | Q4 2023 Earnings Call Transcript |
Recursion Pharmaceuticals: Recent Readouts Disappointing, Future Readouts Risky
Nano-X Imaging: Still Too Early To Invest
Nvidia's Recent Troubles Should Be Absorbed By The Big Picture (Upgrade)
Recursion: Transforming Drug Discovery With Its AI-Powered Drug Development Platform
Recursion Pharmaceuticals: More Of A TechBio Industrializing Drug Discovery
Doubling Down On Gain Therapeutics
Recursion Pharmaceuticals: Second Half 2024 Data Readouts Are Major Inflection Points
Recursion Pharmaceuticals: Leveraging AI To Decode Biology And Discover Novel Therapeutics
Nvidia: Market Share Decline In AI Seems Certain
-
What's the price of Recursion Pharmaceuticals stock today?
One share of Recursion Pharmaceuticals stock can currently be purchased for approximately $5.01.
-
When is Recursion Pharmaceuticals's next earnings date?
Unfortunately, Recursion Pharmaceuticals's (RXRX) next earnings date is currently unknown.
-
Does Recursion Pharmaceuticals pay dividends?
No, Recursion Pharmaceuticals does not pay dividends.
-
How much money does Recursion Pharmaceuticals make?
Recursion Pharmaceuticals has a market capitalization of 2.37B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 12.33% to 44.58M US dollars. Recursion Pharmaceuticals made a loss 328.07M US dollars in net income (profit) last year or -$0.4 on an earnings per share basis.
-
What is Recursion Pharmaceuticals's stock symbol?
Recursion Pharmaceuticals, Inc. is traded on the NASDAQ under the ticker symbol "RXRX".
-
What is Recursion Pharmaceuticals's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Recursion Pharmaceuticals?
Shares of Recursion Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Recursion Pharmaceuticals's key executives?
Recursion Pharmaceuticals's management team includes the following people:
- Dr. Shafique Virani M.D. Chief Corporation Devel. Officer(age: 54, pay: $475,230)
- Ms. Tina Marriott Larson Chief Operating Officer & Pres(age: 50, pay: $463,960)
- Dr. Michael Secora Ph.D. Chief Financial Officer(age: 42, pay: $320,860)
- Dr. Christopher C. Gibson Ph.D. Co-Founder, Chief Executive Officer & Director(age: 42, pay: $315,790)
- Dr. Ramona Doyle M.D. Chief Medical Officer(age: 66, pay: $3,670)
-
Is Recursion Pharmaceuticals founder-led company?
Yes, Recursion Pharmaceuticals is a company led by its founder Dr. Christopher C. Gibson Ph.D..
-
How many employees does Recursion Pharmaceuticals have?
As Jul 2024, Recursion Pharmaceuticals employs 500 workers.
-
When Recursion Pharmaceuticals went public?
Recursion Pharmaceuticals, Inc. is publicly traded company for more then 4 years since IPO on 16 Apr 2021.
-
What is Recursion Pharmaceuticals's official website?
The official website for Recursion Pharmaceuticals is recursion.com.
-
Where are Recursion Pharmaceuticals's headquarters?
Recursion Pharmaceuticals is headquartered at 41 South Rio Grande Street, Salt Lake City, UT.
-
How can i contact Recursion Pharmaceuticals?
Recursion Pharmaceuticals's mailing address is 41 South Rio Grande Street, Salt Lake City, UT and company can be reached via phone at +385 2690203.
Recursion Pharmaceuticals company profile:
Recursion Pharmaceuticals, Inc.
recursion.comExchange:
NASDAQ
Full time employees:
500
Industry:
Biotechnology
Sector:
Healthcare
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis. Its preclinical stage product includes REC-3964 to treat Clostridium difficile colitis; REC-64917 for the treat of neural or systemic inflammation; REC-65029 to treat HRD-negative ovarian cancer; REC-648918 to enhance anti-tumor immune; REC-2029 for the treatment of wnt-mutant hepatocellular carcinoma; REC-14221 to treat solid and hematological malignancies; and REC-64151 for the treatment of immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
41 South Rio Grande Street
Salt Lake City, UT 84101
Salt Lake City, UT 84101
CIK: 0001601830
ISIN: US75629V1044
CUSIP: 75629V104
